Back to Newsroom

Ocata’s Hemangio-derived Mesenchymal Cells Preserve Kidney Function and Extend Lifespan in Preclinical Model of Lupus Nephritis

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of regenerative medicine, reported in Scientific Reports ‒ a Nature Group journal ‒ that its proprietary hemangio-derived mesenchymal cell (HMCTM) technology can be used to prevent the progression of fatal lupus nephritis in NZB/W F1 mice, a classic, well-studied spontaneous model for systemic lupus erythematosus (SLE).

Click here to read more